Brown Advisory’s Metagenomi Therapeutics MGX Stock Holding History

Brown Advisory’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-25,006	Closed	-$37K	–	1427
2025 Q2	$37K	Hold	25,006	–	–	﹤0.01%	1344
2025 Q1	$34K	Hold	25,006	–	–	﹤0.01%	1313
2024 Q4	$90.3K	Hold	25,006	–	–	﹤0.01%	1316
2024 Q3	$54.3K	Buy	+25,006	New	+$86.8K	﹤0.01%	1250

Other funds holding MGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SVGI

Sozo Ventures GP II Redwood City, California $1.33M AUM 9.22% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Brown Advisory's MGX Position: Q3 2025 in Review

Brown Advisory sold out of Metagenomi Therapeutics (MGX) in Q3 2025, closing a stake of 25,006 shares — an estimated $37K sold.

Brown Advisory first reported a position in MGX in Q3 2024 and held it in 4 quarters. The position peaked at $90.3K in Q4 2024. 58 funds tracked by Wall St. Rank hold MGX as of Q3 2025.

Brown Advisory reported no remaining Metagenomi Therapeutics position as of Q3 2025 after selling out during the quarter.
Brown Advisory sold 25,006 Metagenomi Therapeutics shares in Q3 2025, an estimated $37K.
Brown Advisory first reported a position in Metagenomi Therapeutics in Q3 2024 and held it in 4 quarters.
Brown Advisory's Metagenomi Therapeutics position peaked at $90.3K in Q4 2024.
58 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q3 2025.

Based on Brown Advisory's 13F filing for Q3 2025, filed 14 Nov 2025.